Compare USPH & AMPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | USPH | AMPH |
|---|---|---|
| Founded | 1990 | 1996 |
| Country | United States | United States |
| Employees | 5500 | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 1996 | 2005 |
| Metric | USPH | AMPH |
|---|---|---|
| Price | $82.59 | $20.03 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $106.50 | $30.29 |
| AVG Volume (30 Days) | 208.2K | ★ 436.4K |
| Earning Date | 01-01-0001 | 06-01-2026 |
| Dividend Yield | ★ 2.22% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 1.42 | ★ 2.03 |
| Revenue | ★ $780,990,000.00 | $719,887,000.00 |
| Revenue This Year | $9.20 | $7.34 |
| Revenue Next Year | $5.73 | $4.81 |
| P/E Ratio | $58.30 | ★ $10.34 |
| Revenue Growth | ★ 16.33 | N/A |
| 52 Week Low | $62.77 | $19.83 |
| 52 Week High | $93.50 | $31.26 |
| Indicator | USPH | AMPH |
|---|---|---|
| Relative Strength Index (RSI) | 46.64 | 23.94 |
| Support Level | $81.46 | N/A |
| Resistance Level | $88.69 | $28.56 |
| Average True Range (ATR) | 3.28 | 1.23 |
| MACD | -0.48 | -1.00 |
| Stochastic Oscillator | 51.74 | 1.81 |
US Physical Therapy Inc through its subsidiaries operates outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries. The principal payment sources for the clinics' services are managed care programs, commercial health insurance, Medicare/Medicaid, workers' compensation insurance, and proceeds from personal injury cases. Its operating segment includes Physical therapy operations and Industrial injury prevention services. The company generates maximum revenue from the Physical therapy operations segment.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.